Ten deaths possibly linked to a new class of type 2 diabetes drugs is prompting Japanese drug regulators to request manufacturers to add new warnings to the drugs’ labels. The diabetes drugs, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, reduce blood sugar levels by eliminating excessive glucose from the body by inhibiting a protein that helps reabsorb sugar in the urine back into the blood. Since April, the Japanese health ministry has approved six SGLT2 inhibitors. Only three are approved in the U.S. – Jardiance (empagliflozin), Invokana (canagliflozin), and Farxiga (dapagliflozin). SGLT2 inhibitors have been associated with weight loss, which can ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.